Skip to content

Study · Randomized controlled trial · n = 49 · 2012

4 results

Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.

Li ZQ, Quan Z, Tian HL, Cheng M

The Journal of international medical research1 Jan 2012Cited by 35 (Europe PMC)

PMID22613412 (opens in a new tab)DOI10.1177/147323001204000213 (opens in a new tab)PepBankPUB-22613412
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acromegaly with invasive pituitary macroadenoma, cure was significantly more frequent with preoperative lanreotide: 11 of 24 versus five of 25 with direct surgery.

    In plain wordsIn acromegaly, significantly more patients achieved surgical cure with preoperative lanreotide: 11 of 24 versus five of 25 with direct surgery.

    Peptide
    Lanreotide
    Outcome
    IncreaseSurgical cure
    Study

    n = 49

    Comparator
    Direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 2 weeks, increased to 30 mg/week at week 8 if GH nadir >2.5 μg/l · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Patients cured
    11 patients
    preoperative lanreotide group, 24 patients
    Patients cured
    5 patients
    direct surgery group, 25 patients

    Source sentences

    Summary
    According to combined growth hormone and IGF-1 levels, significantly more patients were cured by trans-sphenoidal surgery in the pretreatment group compared with the direct surgery group (11 of 24 and five of 25 patients, respectively).
    3 context sentences
    Summary · context
    To investigate whether 3 months' preoperative treatment with lanreotide improved outcome in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma.
    Summary · context
    After baseline evaluation, untreated patients were randomized to undergo direct transsphenoidal surgery or lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l), for 3 months prior to surgery.
    Summary · context
    Cure was evaluated at 3 months postsurgery by measuring growth hormone and insulinlike growth factor-1 (IGF-1) levels.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acromegaly with invasive pituitary macroadenoma, GH was lower after preoperative lanreotide than after direct surgery at 3 months postsurgery.

    In plain wordsIn acromegaly, growth hormone was lower with preoperative lanreotide than with direct surgery at 3 months postsurgery.

    Peptide
    Lanreotide
    Outcome
    DecreasePostoperative GH
    Study

    n: not reported in source

    Comparator
    Direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 2 weeks, increased to 30 mg/week at week 8 if GH nadir >2.5 μg/l · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Growth hormone and IGF-1 levels were lower in the pretreatment group than in the direct surgery group at 3 months postsurgery.
    3 context sentences
    Summary · context
    To investigate whether 3 months' preoperative treatment with lanreotide improved outcome in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma.
    Summary · context
    After baseline evaluation, untreated patients were randomized to undergo direct transsphenoidal surgery or lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l), for 3 months prior to surgery.
    Summary · context
    Cure was evaluated at 3 months postsurgery by measuring growth hormone and insulinlike growth factor-1 (IGF-1) levels.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acromegaly with invasive pituitary macroadenoma, IGF-1 was lower after preoperative lanreotide than after direct surgery at 3 months postsurgery.

    In plain wordsIn acromegaly, IGF-1 was lower with preoperative lanreotide than with direct surgery at 3 months postsurgery.

    Peptide
    Lanreotide
    Outcome
    DecreasePostoperative IGF-1
    Study

    n: not reported in source

    Comparator
    Direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 2 weeks, increased to 30 mg/week at week 8 if GH nadir >2.5 μg/l · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Growth hormone and IGF-1 levels were lower in the pretreatment group than in the direct surgery group at 3 months postsurgery.
    3 context sentences
    Summary · context
    To investigate whether 3 months' preoperative treatment with lanreotide improved outcome in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma.
    Summary · context
    After baseline evaluation, untreated patients were randomized to undergo direct transsphenoidal surgery or lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l), for 3 months prior to surgery.
    Summary · context
    Cure was evaluated at 3 months postsurgery by measuring growth hormone and insulinlike growth factor-1 (IGF-1) levels.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly with invasive pituitary macroadenoma, preoperative lanreotide significantly reduced mean tumor size.

    In plain wordsIn acromegaly with invasive pituitary macroadenoma, preoperative lanreotide significantly reduced mean tumor size.

    Peptide
    Lanreotide
    Outcome
    DecreaseMean tumor size
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    30 mg every 2 weeks, increased to 30 mg/week at week 8 if GH nadir >2.5 μg/l · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Preoperative lanreotide treatment significantly reduced mean tumour size.
    3 context sentences
    Summary · context
    To investigate whether 3 months' preoperative treatment with lanreotide improved outcome in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma.
    Summary · context
    After baseline evaluation, untreated patients were randomized to undergo direct transsphenoidal surgery or lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l), for 3 months prior to surgery.
    Summary · context
    Cure was evaluated at 3 months postsurgery by measuring growth hormone and insulinlike growth factor-1 (IGF-1) levels.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.